Cargando…

Effect of Direct Bilirubin Level on Clinical Outcome and Prognoses in Severely/Critically Ill Patients With COVID-19

OBJECTIVES: We aimed to investigate how changes in direct bilirubin (DBiL) levels in severely/critically ill the coronavirus disease (COVID-19) patients during their first week of hospital admission affect their subsequent prognoses and mortality. METHODS: We retrospectively enrolled 337 severely/cr...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Wensen, Liu, Hanting, Yang, Gang, Wang, Wei, Liu, Qiongfang, Huang, Chaolin, Zou, Zhuoru, Liu, Yun, Zhuang, Guihua, Zhang, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996189/
https://www.ncbi.nlm.nih.gov/pubmed/35419371
http://dx.doi.org/10.3389/fmed.2022.843505
_version_ 1784684441947340800
author Chen, Wensen
Liu, Hanting
Yang, Gang
Wang, Wei
Liu, Qiongfang
Huang, Chaolin
Zou, Zhuoru
Liu, Yun
Zhuang, Guihua
Zhang, Lei
author_facet Chen, Wensen
Liu, Hanting
Yang, Gang
Wang, Wei
Liu, Qiongfang
Huang, Chaolin
Zou, Zhuoru
Liu, Yun
Zhuang, Guihua
Zhang, Lei
author_sort Chen, Wensen
collection PubMed
description OBJECTIVES: We aimed to investigate how changes in direct bilirubin (DBiL) levels in severely/critically ill the coronavirus disease (COVID-19) patients during their first week of hospital admission affect their subsequent prognoses and mortality. METHODS: We retrospectively enrolled 337 severely/critically ill COVID-19 patients with two consecutive blood tests at hospital admission and about 7 days after. Based on the trend of the two consecutive tests, we categorized patients into the normal direct bilirubin (DBiL) group (224), declined DBiL group (44) and elevated DBiL group (79). RESULTS: The elevated DBiL group had a significantly larger proportion of critically ill patients (χ(2)-test, p < 0.001), a higher risk of ICU admission, respiratory failure, and shock at hospital admission (χ(2)-test, all p < 0.001). During hospitalization, the elevated DBiL group had significantly higher risks of shock, acute respiratory distress syndrome (ARDS), and respiratory failure (χ(2)-test, all p < 0.001). The same findings were observed for heart damage (χ(2)-test, p = 0.002) and acute renal injury (χ(2)-test, p = 0.009). Cox regression analysis showed the risk of mortality in the elevated DBiL group was 2.27 (95% CI: 1.50–3.43, p < 0.001) times higher than that in the normal DBiL group after adjusted age, initial symptom, and laboratory markers. The Receiver Operating Characteristic curve (ROC) analysis demonstrated that the second test of DBiL was consistently a better indicator of the occurrence of complications (except shock) and mortality than the first test in severely/critically ill COVID-19 patients. The area under the ROC curve (AUC) combined with two consecutive DBiL levels for respiratory failure and death was the largest. CONCLUSION: Elevated DBiL levels are an independent indicator for complication and mortality in COVID-19 patients. Compared with the DBiL levels at admission, DBiL levels on days 7 days of hospitalization are more advantageous in predicting the prognoses of COVID-19 in severely/critically ill patients.
format Online
Article
Text
id pubmed-8996189
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89961892022-04-12 Effect of Direct Bilirubin Level on Clinical Outcome and Prognoses in Severely/Critically Ill Patients With COVID-19 Chen, Wensen Liu, Hanting Yang, Gang Wang, Wei Liu, Qiongfang Huang, Chaolin Zou, Zhuoru Liu, Yun Zhuang, Guihua Zhang, Lei Front Med (Lausanne) Medicine OBJECTIVES: We aimed to investigate how changes in direct bilirubin (DBiL) levels in severely/critically ill the coronavirus disease (COVID-19) patients during their first week of hospital admission affect their subsequent prognoses and mortality. METHODS: We retrospectively enrolled 337 severely/critically ill COVID-19 patients with two consecutive blood tests at hospital admission and about 7 days after. Based on the trend of the two consecutive tests, we categorized patients into the normal direct bilirubin (DBiL) group (224), declined DBiL group (44) and elevated DBiL group (79). RESULTS: The elevated DBiL group had a significantly larger proportion of critically ill patients (χ(2)-test, p < 0.001), a higher risk of ICU admission, respiratory failure, and shock at hospital admission (χ(2)-test, all p < 0.001). During hospitalization, the elevated DBiL group had significantly higher risks of shock, acute respiratory distress syndrome (ARDS), and respiratory failure (χ(2)-test, all p < 0.001). The same findings were observed for heart damage (χ(2)-test, p = 0.002) and acute renal injury (χ(2)-test, p = 0.009). Cox regression analysis showed the risk of mortality in the elevated DBiL group was 2.27 (95% CI: 1.50–3.43, p < 0.001) times higher than that in the normal DBiL group after adjusted age, initial symptom, and laboratory markers. The Receiver Operating Characteristic curve (ROC) analysis demonstrated that the second test of DBiL was consistently a better indicator of the occurrence of complications (except shock) and mortality than the first test in severely/critically ill COVID-19 patients. The area under the ROC curve (AUC) combined with two consecutive DBiL levels for respiratory failure and death was the largest. CONCLUSION: Elevated DBiL levels are an independent indicator for complication and mortality in COVID-19 patients. Compared with the DBiL levels at admission, DBiL levels on days 7 days of hospitalization are more advantageous in predicting the prognoses of COVID-19 in severely/critically ill patients. Frontiers Media S.A. 2022-03-28 /pmc/articles/PMC8996189/ /pubmed/35419371 http://dx.doi.org/10.3389/fmed.2022.843505 Text en Copyright © 2022 Chen, Liu, Yang, Wang, Liu, Huang, Zou, Liu, Zhuang and Zhang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Chen, Wensen
Liu, Hanting
Yang, Gang
Wang, Wei
Liu, Qiongfang
Huang, Chaolin
Zou, Zhuoru
Liu, Yun
Zhuang, Guihua
Zhang, Lei
Effect of Direct Bilirubin Level on Clinical Outcome and Prognoses in Severely/Critically Ill Patients With COVID-19
title Effect of Direct Bilirubin Level on Clinical Outcome and Prognoses in Severely/Critically Ill Patients With COVID-19
title_full Effect of Direct Bilirubin Level on Clinical Outcome and Prognoses in Severely/Critically Ill Patients With COVID-19
title_fullStr Effect of Direct Bilirubin Level on Clinical Outcome and Prognoses in Severely/Critically Ill Patients With COVID-19
title_full_unstemmed Effect of Direct Bilirubin Level on Clinical Outcome and Prognoses in Severely/Critically Ill Patients With COVID-19
title_short Effect of Direct Bilirubin Level on Clinical Outcome and Prognoses in Severely/Critically Ill Patients With COVID-19
title_sort effect of direct bilirubin level on clinical outcome and prognoses in severely/critically ill patients with covid-19
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996189/
https://www.ncbi.nlm.nih.gov/pubmed/35419371
http://dx.doi.org/10.3389/fmed.2022.843505
work_keys_str_mv AT chenwensen effectofdirectbilirubinlevelonclinicaloutcomeandprognosesinseverelycriticallyillpatientswithcovid19
AT liuhanting effectofdirectbilirubinlevelonclinicaloutcomeandprognosesinseverelycriticallyillpatientswithcovid19
AT yanggang effectofdirectbilirubinlevelonclinicaloutcomeandprognosesinseverelycriticallyillpatientswithcovid19
AT wangwei effectofdirectbilirubinlevelonclinicaloutcomeandprognosesinseverelycriticallyillpatientswithcovid19
AT liuqiongfang effectofdirectbilirubinlevelonclinicaloutcomeandprognosesinseverelycriticallyillpatientswithcovid19
AT huangchaolin effectofdirectbilirubinlevelonclinicaloutcomeandprognosesinseverelycriticallyillpatientswithcovid19
AT zouzhuoru effectofdirectbilirubinlevelonclinicaloutcomeandprognosesinseverelycriticallyillpatientswithcovid19
AT liuyun effectofdirectbilirubinlevelonclinicaloutcomeandprognosesinseverelycriticallyillpatientswithcovid19
AT zhuangguihua effectofdirectbilirubinlevelonclinicaloutcomeandprognosesinseverelycriticallyillpatientswithcovid19
AT zhanglei effectofdirectbilirubinlevelonclinicaloutcomeandprognosesinseverelycriticallyillpatientswithcovid19